Solventum Corporation Q1 2026 Earnings Recap

SOLV Q1 2026 May 6, 2026

Get alerts when SOLV reports next quarter

The stock rose 5.3% following first quarter earnings that outperformed expectations, driven by stronger-than-anticipated organic sales growth, EPS, and margins. Positive momentum across all segments and early success with the recent Acera acquisition propelled investor enthusiasm.

Earnings Per Share Beat

$1.48 vs $1.35 est.

+9.6% surprise

Revenue Beat

2007000000 vs 1967430000 est.

+2.0% surprise

Market Reaction

1-Day +0.93%

5-Day +4.41%

30-Day +6.97%

See SOLV alongside your other holdings

Add to your portfolio — free

Key Takeaways

Organic sales growth and EPS exceeded company plans, reflecting effective commercial execution and new product launches.
Margin performance was better than expected, supported by volume, mix, and ongoing savings initiatives.
The acquisition of Acera is off to a promising start, complementing the wound care portfolio and expected to contribute meaningfully during the year.
Transformation efforts including ERP cutovers, portfolio optimization, and the $500 million Transform for the Future savings program are progressing well.
Board-approved share buybacks (up to $1 billion) signal confidence in the valuation and financial flexibility.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit SOLV on AllInvestView.

Previous Q3 2025